Haldol

Haldol is a prescription medication whose active ingredient is haloperidol, a butyrophenone antipsychotic. It is supplied in oral dosage forms, though specific strengths may vary by market. Haloperidol works primarily as a dopamine D2 receptor antagonist and is classified under ATC code N05AD01. The product is marketed in the European Union and is intended for use under medical supervision for certain psychiatric conditions and treatment.

Haloperidol is prescribed for several psychiatric and neurological conditions where dopamine blockade is beneficial.

- Schizophrenia, for both acute exacerbations and long‑term maintenance therapy to reduce positive symptoms such as hallucinations and delusions. - Acute psychosis or severe agitation, where rapid control of symptoms is required, often administered in hospital settings. - Tourette syndrome, particularly for patients with persistent motor and vocal tics not adequately controlled by first‑line agents. - Short‑term management of acute mania, delirium, or severe behavioral disturbance when alternative antipsychotics are contraindicated. - Adjunctive use in dementia‑related aggression or psychosis, recognizing that this is an off‑label indication in many jurisdictions.

Haloperidol may cause a range of side effects, varying in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, akathisia, or dystonia. - Dry mouth, constipation, or blurred vision. - Weight gain or increased appetite. - Orthostatic hypotension. - Nausea or vomiting.

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder. - Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability. - Cardiac arrhythmias, including QT prolongation, which can lead to serious ventricular tachyarrhythmias.

When prescribing haloperidol, clinicians consider several precautions to minimize risks and ensure safe use.

- Assess patient history for cardiovascular disease, as haloperidol can affect heart rhythm. - Monitor for signs of extrapyramidal symptoms, especially in elderly patients. - Use the lowest effective dose for the shortest duration needed. - Evaluate liver and kidney function periodically, since impairment may alter drug clearance. - Caution in patients with a history of seizures or neuroleptic malignant syndrome. - Avoid use during pregnancy unless benefits outweigh risks, due to limited safety data.

Haloperidol can interact with other medications, influencing its effectiveness or increasing adverse effects.

Avoid: - Other dopamine‑blocking agents, which may amplify extrapyramidal side effects. - Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution: - CNS depressants like benzodiazepines or opioids, which can increase sedation. - Anticholinergic drugs, which may mask early signs of extrapyramidal symptoms. - Lithium, as combined use may affect neurological status.